Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension

References

• Tsukamoto H, Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and dorzolamide, alone and in combination. Arch Ophthalmol 2004;122:190–3
   PubMed Web of Science ®Google Scholar
• Wang RF, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol 1991;109:1297–9
   PubMed Web of Science ®Google Scholar
• Trusopt [package insert]. Whitehouse Station (NJ): Merck & Co, Inc; 1998
   Google Scholar
• Ott EZ, Mills MD, Arango S, et al. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch Ophthalmol 2005;123:1177–86
   PubMed Web of Science ®Google Scholar
• Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS 1998;2:43–7
   Google Scholar
• Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 1997;104:137–42
   PubMed Web of Science ®Google Scholar
• Strahlman E, Tipping R Vogel R; International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995;113: 1009–16
   Google Scholar
• Toris CB, Camras CB Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8–14
   PubMed Web of Science ®Google Scholar
• Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(Suppl):S27–S37
   Google Scholar
• LeBlanc RP; Brimonidine Study Group 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998;105: 1960–7
   Google Scholar
• Katz LJ; Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol 1999;127: 20–6
   Google Scholar
• Bowman RJC, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004;18: 24–6
   Google Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001;5:281–4
   PubMed Web of Science ®Google Scholar
• Alphagan [package insert]. Irvine (CA):Allergan, Inc.; 2001
   Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine–purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119–26
   PubMed Web of Science ®Google Scholar
• Dong JQ, Babusis DM, Welty DF, et al. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 2004;20:285–92
   PubMed Web of Science ®Google Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205–15
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490–6
   Google Scholar
• Camras CB, Sheu W-P. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma 2005:14:161–7
   Google Scholar
• van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177–85
   PubMed Web of Science ®Google Scholar
• Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000;16:251–9
   Google Scholar
• Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002;109:307–14
   PubMed Web of Science ®Google Scholar
• Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health-Syst Pharm 2005;62:691–9
   PubMed Web of Science ®Google Scholar
• Stewart WC, Sharpe ED, Harbin Jr TS, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000;129: 723–7
   Google Scholar
• Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13:168–73
   PubMed Web of Science ®Google Scholar
• Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2004;88:953–6
   Google Scholar
• Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917–23
   PubMed Web of Science ®Google Scholar
• Hegde V, Robinson R, Dean F, et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007;114:362–6
   PubMed Web of Science ®Google Scholar
• Carrasco Font C, Arias Puente A, Garcia Saenz MC, et al. Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers. Arch Soc Esp Oftalmol 2004;79:163–8
   Google Scholar
• Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001;23:604–19
   Google Scholar
• Hommer A, Kapik B, Shams N. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Br J Ophthalmol 2003;87:592–8
   Google Scholar
• Sodhi PK, Pandey RM, Ratan SK. Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma. Int J Clin Pract 2003;57: 875–8
   Google Scholar
• Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603–8
   PubMed Web of Science ®Google Scholar
• Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982;93:232–7
   Google Scholar
• Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol 2001;119:492–5
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Yablonski ME, et al. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. J Glaucoma 2004;13:210–5
   PubMed Web of Science ®Google Scholar
• Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 2001;10:220–6
   PubMed Web of Science ®Google Scholar
• Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/ timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149–57
   PubMed Web of Science ®Google Scholar
• Adamsons I, Clineschmidt C, Polis A, et al.; Additivity Study Group. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. J Glaucoma 1998;7:253–60
   Google Scholar
• Hartenbaum D, Maloney S, Vaccarelli L, et al. Comparison of dorzolamide and pilocarpine as adjunctive therapy in patients with open-angle glaucoma and ocular hypertension. Clin Ther 1999;21:1533–8
   PubMed Web of Science ®Google Scholar
• Petounis A, Mylopoulos N, Kandarakis A, et al. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. J Glaucoma 2001;10: 316–24
   PubMed Web of Science ®Google Scholar
• Garcia-Sanchez J; Spanish Latanoprost Study Group. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension – a three-month randomised study. Eur J Ophthalmol 2000;10:198–204
   Google Scholar
• Hutzelmann J, Owens S, Shedden A, et al.; International Clinical Equivalence Study Group. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br J Ophthalmol 1998;82: 1249–53
   Google Scholar
• Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension: a 3-month randomised study. Graefes Arch Clin Exp Ophthalmol 2000;238:19–23
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al.; Dorzolamide-Timolol Study Group. The efficacy and safety of the dorzolamide– timolol combination versus the concomitant administration of its components. Ophthalmology 1998;105:1936–44
   Google Scholar
• Centofanti M, Manni G, Gregori D, et al. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefes Arch Clin Exp Ophthalmol 2000;238:302–5
   PubMed Web of Science ®Google Scholar
• O’Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836–7
   Google Scholar
• Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95–104
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84
   PubMed Web of Science ®Google Scholar
• Parrish R, Palmberg P, Sheu W-P, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2003;135: 688–703
   Google Scholar
• Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther 2004;21:247–62
   Google Scholar
• Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100: 1297–304
   Google Scholar
• Travatan [package insert]. Fort Worth (TX): Alcon Laboratories, Inc.; 2001
   Google Scholar
• Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003;48(Suppl):S17–S20
   Google Scholar
• Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004;111:1658–62
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al.; Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzolamidetimolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998;105:1945–51
   Google Scholar
• Clineschmidt CM, Williams RD, Snyder E, et al.; Dorzolamide-Timolol Combination Study Group. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide–timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1998;105:1952–9
   Google Scholar
• Cosopt [package insert]. Whitehouse Station (NJ): Merck & Co, Inc.; 2006
   Google Scholar
• Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337–48
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124: 1230–8
   Google Scholar
• Goñi FJ; Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15: 581–90
   Google Scholar
• Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003;110:615–24
   Google Scholar
• Arcieri ES, Arcieri RS, Pereira AC, et al. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin 2007:23:683–9
   PubMed Web of Science ®Google Scholar
• Wayman L, Larsson LI, Maus T, et al. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:1368–71
   PubMed Web of Science ®Google Scholar
• Vetrugno M, Sisto D, Trabucco T, et al. Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. J Ocul Pharmacol Ther 2005;21:250–7
   PubMed Web of Science ®Google Scholar
• Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514–7
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9: 134–42
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111: 1627–35
   Google Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma 2004;13:130–6
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132–5
   PubMedGoogle Scholar
• Osborne SA, Montgomery DMI, Morris D, McKay IC. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19:129–37
   PubMed Web of Science ®Google Scholar
• Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13: 163–7
   PubMed Web of Science ®Google Scholar
• Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine–0.5% timolol. Arch Ophthalmol 2007; 125:717
   PubMed Web of Science ®Google Scholar